Tissue-specific estrogenic response and molecular mechanisms

Toxicology Letters

Volumn 127, Issue 1-3, 2002, Pages 217-224

  Diel, Patrick ^a  

^a GERMAN SPORT UNIVERSITY COLOGNE   (Germany)

Author keywords

Environmental estrogens; Estrogen; Selective estrogen receptor

Indexed keywords

ANTIESTROGEN; ESTROGEN; ESTROGEN BINDING PROTEIN; ESTROGEN DERIVATIVE; ESTROGEN RECEPTOR; LIGAND; RALOXIFENE; RECEPTOR; RECEPTOR SUBTYPE; REGULATOR PROTEIN; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN;

ANALYTIC METHOD; BONE; BRAIN; BREAST; CARDIOVASCULAR SYSTEM; COMPLEX FORMATION; CONFERENCE PAPER; DNA RESPONSIVE ELEMENT; DRUG ACTIVITY; DRUG MECHANISM; ENDOMETRIUM; GENETIC TRANSCRIPTION; HORMONE ACTION; HORMONE RESPONSE; LIVER; MOLECULAR MECHANICS; PRIORITY JOURNAL; PROTEIN INTERACTION; REGULATORY MECHANISM; TARGET CELL; TISSUE DIFFERENTIATION; TISSUE GROWTH; TISSUE SPECIFICITY;

ANIMALS; BREAST; CELL DIVISION; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; ESTROGENS; FEMALE; HUMANS; MALE; MODELS, BIOLOGICAL; PROSTATE; RECEPTOR CROSS-TALK; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TAMOXIFEN; UTERUS;

EID: 0037186894     PISSN: 03784274     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-4274(01)00503-3     Document Type: Conference Paper

References (42)

1. Proteasome-mediated proteolysis of estrogen receptor: A novel component in autologous down-regulation
2. A realistic clinical perspective of tamoxifen and endometrial carcinogenesis
3. Raloxifene (LY139481 HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats
4. Epidemiology of breast cancer. Findings from the nurses' health study
5. The effect of raloxifene on risk of breast cancer in postmenopausal women: Results from the MORE randomized trial. Multiple outcomes of raloxifene evaluation
6. Ability of xeno- and phytoestrogens to modulate expression of estrogen-sensitive genes in rat uterus: Estrogenic profiles and uterotropic activity
7. Phytoestrogens and carcinogenesis - Differential effects of genistein in experimental models of normal and malignant rat endometrium
8. Molecular identification of potential selective estrogen receptor modulator (SERM) like properties of pfytoestrogens in the human breast cancer cell line MCF-7
9. Observations in a preliminary open trial of estradiol therapy for senile dementia - Alzheimer's type
10. Activation, transformation, and subunit structure of steroid hormone receptors
11. Control of transcription activation by steroid hormone receptors
12. Estrogen use and cardiovascular disease
13. Estrogen control of progesterone receptor in human breast cancer: Role of estradiol and antiestrogen
14. Nuclear receptor coactivators and corepressors
15. The partial agonist activity of antagonist-occupied steroid receptors is controlled by a novel hinge domain-binding coactivator L7/SPA and the corepressors N-CoR or SMRT
16. Basic guides to the mechanism of estrogen action
17. A two-step mechanism for the interaction of estradiol with rat uterus
18. Should clinicians be concerned about the carcinogenic potential of tamoxifen?
19. Monoclonal antibodies localize oestrogen receptor in the nuclei of target cells
20. Transcription factor-specific requirements for coactivators and their acetyltransferase functions
21. The novel estrogen receptor-beta subtype: Potential role in the cell- and promoter-specific actions of estrogens and anti-estrogens
22. Cloning of a novel receptor expressed in rat prostate and ovary
23. Diverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes
24. The estrogen receptor activity cycle: Dependence on multiple protein-protein interactions
25. Effects of tamoxifen on cardiovascular risk factors in postmenopausal women
26. Molecular determinants of the estrogen receptor-coactivator interface
27. An estrogen receptor-selective coregulator that potentiates the effectiveness of antiestrogens and represses the activity of estrogens
28. Proteasome-dependent degradation of the human estrogen receptor
29. Molecular cloning and characterization of human estrogen receptor betacx: A potential inhibitor of estrogen action in human
30. Sequence and characterization of a coactivator for the steroid hormone receptor superfamily
31. The steroid receptor coactivator-1 contains multiple receptor interacting and activation domains that cooperatively enhance the activation function 1 (AF1) and AF2 domains of steroid receptors
32. Structure of the ligand-binding domain of oestrogen receptor beta in the presence of a partial agonist and a full antagonist
33. Cell membrane and nuclear estrogen receptors (ERs) originate from a single transcript: Studies of ERalpha and ERbeta expressed in Chinese hamster ovary cells
34. The quaternary structures of untransformed steroid hormone receptors: An open issue
35. Modulation of the ligand-independent activation of the human estrogen receptor by hormone and antihormone
36. CREB binding protein acts synergistically with steroid receptor coactivator-1 to enhance steroid receptor-dependent transcription
37. Coactivator and corepressor regulation of the agonist/antagonist activity of the mixed antiestrogen, 4-hydroxytamoxifen
38. Dominant activity of activation function 1 (Af-1) and differential stoichiometric requirements for AF-1 and -2 in the estrogen receptor alpha-beta heterodimeric complex
39. Raloxifene preserves bone strength and bone mass in ovariectomized rats
40. Identification of a dominant negative form of the human estrogen receptor
41. Interactions controlling the assembly of nuclear-receptor heterodimers and co-activators
42. Partial hormone resistance in mice with disruption of the steroid receptor coactivator-1 (SRC-1) gene